IDYA · IDEAYA Biosciences, Inc. · Stock research

Current Thesis

IDEAYA has crossed from "clinical-stage story" to "approval trade." The registrational Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in first-line HLAA2-negative metastatic uveal melanoma met its primary endpoint (HR 0.42; median PFS 6.9 vs 3.1 months; ORR 37.1% vs 5.8% with 5 complete responses), with complete data delivered in an ASCO late-breaking oral on 2026-06-01. The company began a rolling NDA under the FDA Oncology Center of Excellence Real-Time Oncology Review (RTOR) program — first pre-submission module in May, filing completion guided to H2 2026, with fast track designation. This is the leg an investor buys: a de-risked pivotal readout feeding a rolling submission toward the first US approval in an indication with no approved 1L standard for HLAA2-negative patients. The balance sheet removes the classic biotech tail risk — $972.9M cash at 2026-03-31 (runway into 2030), topped up by a $300M raise on 2026-06-09. Price has reclaimed to ~$35.40 (2026-07-24), roughly 31% above the $27.00 offering, so the June deal financed strength, not a rescue. The nearest tell is the 2026-08-04 Q2 print, where NDA filing timing gets updated.

Bullish and bearish views on IDEAYA Biosciences, Inc.

The model's bull view on IDEAYA Biosciences, Inc. (IDYA), in brief: OptimUM-02 primary endpoint hit hard: HR 0.42, median PFS 6.9 vs 3.1 months, ORR 37.1% vs 5.8%, 5 complete responses in the darovasertib+crizotinib arm — complete data at ASCO 2026-06-01. The bear view: The easy de-risking is done. With OptimUM-02 positive and the raise absorbed, the remaining catalysts (NDA acceptance, label, HLA*A2-positive OptimUM-01 data) are incremental relative to the pivotal readout that already re-rated the stock off $27. Analyst revisions still point… Both cases follow in full.

Bull Case

• OptimUM-02 primary endpoint hit hard: HR 0.42, median PFS 6.9 vs 3.1 months, ORR 37.1% vs 5.8%, 5 complete responses in the darovasertib+crizotinib arm — complete data at ASCO 2026-06-01. The largest binary in the story is already behind the tape.
• Regulatory path is short and expedited: rolling NDA under FDA RTOR, first pre-submission module May 2026, completion guided H2 2026, fast track designation — a structure that can compress the gap from filing to decision versus a standard review.
• Fortress balance sheet: $972.9M cash/marketable securities at 2026-03-31 with runway guided into 2030, plus the $300M gross raise priced 2026-06-09 (5,555,556 shares + pre-funded warrants at $27.00). Financing overhang that dominated the June narrative is now cleared for years.
• Non-dilutive validation from Servier (partnership signed Aug 2025): $210M upfront, up to $320M in milestones, double-digit royalties, and shared development cost on darovasertib — a large-pharma partner underwriting the ex-US build-out.
• Second pipeline pillar maturing: IDE849 (SHR-4849), a DLL3-TOP1 ADC partnered with Hengrui, posted positive Phase 1 data in small-cell lung and neuroendocrine carcinomas (100 patients), with long-term data due at ESMO 2026 and a first registrational trial targeted to start by year-end 2026 — leverage to the same DLL3-ADC wave that re-rated the space.
• Takeout optionality is live: GSK's $10.6B acquisition of Nuvalent (announced 2026-06-09) confirms big-pharma appetite for near-approval precision oncology, and IDEAYA already runs a GSK Pol-theta collaboration.
• Street still frames wide upside even after the 2026-07-07 target cuts: RBC $48, Truist $63, Wedbush $58 (2026-06-12), average near $52.29 — roughly 47% above spot.

Bear Case

• The easy de-risking is done. With OptimUM-02 positive and the raise absorbed, the remaining catalysts (NDA acceptance, label, HLA*A2-positive OptimUM-01 data) are incremental relative to the pivotal readout that already re-rated the stock off $27.
• Analyst revisions still point down: both RBC and Truist cut targets on 2026-07-07 while maintaining ratings — the direction of estimate travel is lower even as the headline path improved.
• Uveal melanoma is a small addressable market; the commercial ceiling on a first approval is modest until neoadjuvant (OptimUM-09) and HLA*A2-positive expansions read out and convert.
• RTOR is expedited but not guaranteed — a rolling submission can stall on CMC, data-package, or review-division questions, and "H2 2026 filing" is a window, not a fixed date the tape can grade.
• The DLL3-ADC field IDE849 targets is crowded (tarlatamab established, Zai Lab and others active); Phase 1 promise must survive registrational scrutiny.
• Pre-revenue economics: darovasertib collaboration revenue was $6.6M in Q1 2026 (down from $10.9M in Q4 2025); the equity is valued on forward approvals, so any RTOR slip compresses the multiple fast.

Setup & Price Structure

The reference shelf is the 2026-06-09 offering at $27.00; the stock has since built above it, printing ~$37.66 on 2026-07-02 before easing to ~$35.40 by 2026-07-24 — a consolidation that holds the post-data breakout rather than a fresh vertical leg. That behavior reframes the level map: the $27.00 shelf is no longer a "participants underwater" risk but a distant floor roughly 24% below spot. The working structure is a base in the low-to-mid $30s digesting the OptimUM-02 pop, with the July high near $37.66 as the shelf to reclaim for the next leg and the round $30 area as the line that separates "healthy consolidation" from "approval trade being faded." A fresh entry here is buying a constructive base into an expedited regulatory path, not chasing an extended breakout. The wide gap to Street targets ($48–63) is upside only if NDA progress and H2 data updates re-rate it; on a clinical-stage name that gap is a payoff profile, not a valuation cushion. Q2 earnings on 2026-08-04 sits about seven trading sessions out — close enough to keep fresh sizing measured, not yet inside a hard binary-risk blackout.

Catalyst Calendar (next 30 days)

• H2 2026 (window, ongoing): completion of the rolling darovasertib NDA under FDA RTOR — the defining event for the approval trade; incremental module color can leak through the Q2 call.
• Beyond 30d, on the radar — 2026-10-23 to 2026-10-27 (ESMO, Madrid): three darovasertib presentations (OptimUM-02, HLA*A2-positive OptimUM-01, neoadjuvant OptimUM-09) plus Hengrui's long-term IDE849 Phase 1 data in SCLC/NEC.
• Beyond 30d — H2 2026: targeted clinical data update for the darovasertib combination in HLA*A2-positive mUM (OptimUM-01) and initiation of the first IDE849 registrational trial by year-end.

Elapsed catalysts

• 2026-08-04: Q2 2026 earnings and business update — the near-term tell. Watch for confirmation of NDA filing timing (H2 2026), RTOR module cadence, and cash-runway reiteration into 2030. (passed 5d ago)

What Would Change Our Mind

The thesis breaks on a weekly close below $30, which loses the post-OptimUM-02 base and marks a retrace halfway back toward the June $27.00 offering shelf — the signal that the approval trade is being distributed ahead of, not into, the NDA. A secondary invalidation is a regulatory stumble: the darovasertib NDA slipping past its H2 2026 filing window, an FDA refuse-to-file, or a CMC/clinical hold that converts the RTOR shortcut into a standard-review timeline. The third condition is thematic — the oncology-immunology and precision-biotech complex flipping to SATURATED as competing synthetic-lethality and DLL3-ADC readouts capture the takeout bid and the incremental capital, leaving IDEAYA a single-approval story with a small near-term market. Absent those, consolidation above $30 with the NDA advancing keeps the base intact.

Correlation Notes

• Sector beta: trades with XBI and the small/mid-cap biotech complex; rate-sensitive, so a tightening macro regime or a risk-off leg in speculative biotech pressures the multiple independent of pipeline progress.
• Partner-linked exposure: darovasertib economics are shared with Servier (ex-US) and IDE849 with Hengrui — partner pipeline decisions and China-regulatory headlines feed back into the sum-of-parts.
• Idiosyncratic core: uveal-melanoma approval risk is largely single-name and event-driven; the stock decouples from the index around OptimUM/NDA milestones and RTOR headlines more than around broad tape.
• M&A read-through: precision-oncology takeouts (GSK/Nuvalent $10.6B, 2026-06-09) set the comp for takeout optionality; a fresh large-cap acquisition in synthetic lethality or DLL3-ADC would re-rate the whole cohort, including IDYA.
• Theme cohort: moves loosely with other de-risked, near-approval oncology names and the DLL3-ADC group (tarlatamab-adjacent), where a positive peer readout lifts sentiment and a peer failure drains the takeout premium.